CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
The clinical development of chimeric antigen receptor (CAR) T-cell therapy has been more challenging for chronic lymphocytic leukemia (CLL) compared to other settings. One of the main reasons is the CLL-associated state of immune dysfunction that specifically involves patient-derived T cells. Here,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000988 |
| _version_ | 1797226628689952768 |
|---|---|
| author | Candida Vitale Valentina Griggio Francesca Perutelli Marta Coscia |
| author_facet | Candida Vitale Valentina Griggio Francesca Perutelli Marta Coscia |
| author_sort | Candida Vitale |
| collection | DOAJ |
| description | The clinical development of chimeric antigen receptor (CAR) T-cell therapy has been more challenging for chronic lymphocytic leukemia (CLL) compared to other settings. One of the main reasons is the CLL-associated state of immune dysfunction that specifically involves patient-derived T cells. Here, we provide an overview of the clinical results obtained with CAR T-cell therapy in CLL, describing the identified immunologic reasons for the inferior efficacy. Novel CAR T-cell formulations, such as lisocabtagene maraleucel, administered alone or in combination with the Bruton tyrosine kinase inhibitor ibrutinib, are currently under investigation. These approaches are based on the rationale that improving the quality of the T-cell source and of the CAR T-cell product may deliver a more functional therapeutic weapon. Further strategies to boost the efficacy of CAR T cells should rely not only on the production of CAR T cells with an improved cellular composition but also on additional changes. Such alterations could include (1) the coadministration of immunomodulatory agents capable of counteracting CLL-related immunological alterations, (2) the design of improved CAR constructs (such as third- and fourth-generation CARs), (3) the incorporation into the manufacturing process of immunomodulatory compounds overcoming the T-cell defects, and (4) the use of allogeneic CAR T cells or alternative CAR-modified cellular vectors. These strategies may allow to develop more effective CAR-modified cellular therapies capable of counteracting the more aggressive and still incurable forms of CLL. |
| first_indexed | 2024-03-08T19:16:29Z |
| format | Article |
| id | doaj.art-686a8841b4cf4bfb9059511e9ea255c8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-04-24T14:27:56Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-686a8841b4cf4bfb9059511e9ea255c82024-04-03T04:28:36ZengWileyHemaSphere2572-92412023-12-01712e98810.1097/HS9.0000000000000988202312000-00008CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?Candida Vitale0Valentina Griggio1Francesca Perutelli2Marta Coscia31 University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Italy1 University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Italy1 University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Italy1 University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, ItalyThe clinical development of chimeric antigen receptor (CAR) T-cell therapy has been more challenging for chronic lymphocytic leukemia (CLL) compared to other settings. One of the main reasons is the CLL-associated state of immune dysfunction that specifically involves patient-derived T cells. Here, we provide an overview of the clinical results obtained with CAR T-cell therapy in CLL, describing the identified immunologic reasons for the inferior efficacy. Novel CAR T-cell formulations, such as lisocabtagene maraleucel, administered alone or in combination with the Bruton tyrosine kinase inhibitor ibrutinib, are currently under investigation. These approaches are based on the rationale that improving the quality of the T-cell source and of the CAR T-cell product may deliver a more functional therapeutic weapon. Further strategies to boost the efficacy of CAR T cells should rely not only on the production of CAR T cells with an improved cellular composition but also on additional changes. Such alterations could include (1) the coadministration of immunomodulatory agents capable of counteracting CLL-related immunological alterations, (2) the design of improved CAR constructs (such as third- and fourth-generation CARs), (3) the incorporation into the manufacturing process of immunomodulatory compounds overcoming the T-cell defects, and (4) the use of allogeneic CAR T cells or alternative CAR-modified cellular vectors. These strategies may allow to develop more effective CAR-modified cellular therapies capable of counteracting the more aggressive and still incurable forms of CLL.http://journals.lww.com/10.1097/HS9.0000000000000988 |
| spellingShingle | Candida Vitale Valentina Griggio Francesca Perutelli Marta Coscia CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? HemaSphere |
| title | CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? |
| title_full | CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? |
| title_fullStr | CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? |
| title_full_unstemmed | CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? |
| title_short | CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? |
| title_sort | car modified cellular therapies in chronic lymphocytic leukemia is the uphill road getting less steep |
| url | http://journals.lww.com/10.1097/HS9.0000000000000988 |
| work_keys_str_mv | AT candidavitale carmodifiedcellulartherapiesinchroniclymphocyticleukemiaistheuphillroadgettinglesssteep AT valentinagriggio carmodifiedcellulartherapiesinchroniclymphocyticleukemiaistheuphillroadgettinglesssteep AT francescaperutelli carmodifiedcellulartherapiesinchroniclymphocyticleukemiaistheuphillroadgettinglesssteep AT martacoscia carmodifiedcellulartherapiesinchroniclymphocyticleukemiaistheuphillroadgettinglesssteep |